Every year, the influenza A virus evolves just enough to evade the immune systems of millions of people worldwide. Small changes at the genomic level produce new strains that the body no longer recognizes, making annual vaccination a necessity and antiviral research a constant race. A landmark study from the Gulbenkian Institute of Science has now revealed exactly where the influenza A virus assembles its genome inside infected cells, opening the door to a new generation of therapies.
How the Influenza A Virus Replicates Inside Cells
The influenza A virus cannot reproduce on its own. To multiply, it must invade a host cell and co-opt its internal machinery. Once inside, the virus releases its genetic material along with several proteins. What makes this pathogen particularly unusual is that its genome is not a single continuous strand but is instead divided into eight distinct segments. During replication, each of those eight segments is copied thousands of times, producing a massive, disorganized pool of genetic material. For a functional new virus particle to form, one copy of each segment must be selected and packaged together with precision, out of that enormous molecular mixture.
Until recently, the location where that selection occurred was completely unknown.
Viral Inclusions and the Role of Phase Separation
The research team led by Maria João Amorim discovered that the influenza A virus drives infected cells to form specialized compartments called viral inclusions, and it is inside these structures that genome assembly takes place. Unlike conventional cellular organelles, viral inclusions are not enclosed by a membrane. Instead, they maintain their boundaries through a process known as liquid liquid phase separation, the same phenomenon that causes oil and vinegar to remain separate when combined in a container.
This phase separation allows the viral genome segments to concentrate within a confined space, dramatically increasing the efficiency of the assembly process. By corralling thousands of genetic molecules into a smaller, organized environment, the virus can sort and package its eight part genome with far greater precision than would be possible in the open cytoplasm of the cell.
The findings were published in Nature Communications.
What the Influenza A Virus Discovery Means for Treatment
The discovery has significant implications for antiviral drug development. According to Amorim, the results open alternative therapeutic approaches that could target either the genome assembly process itself or the viral inclusions where that assembly occurs. Rather than attacking the virus after it has already replicated, future therapies might disrupt the conditions that allow the influenza A virus to organize its genome in the first place.
The study also contributes to a broader and rapidly growing area of biological research. Phase separation is increasingly understood to play a role in a wide range of diseases, particularly neurological conditions. The IGC team’s work suggests that viral infections, including influenza, may exploit the same fundamental cellular mechanisms implicated in those diseases, which could eventually lead to cross disciplinary treatment strategies.
Understanding how the influenza A virus constructs itself at the molecular level also raises important questions about other segmented RNA viruses that follow similar replication strategies. Researchers believe the phase separation mechanism observed in influenza A may not be unique to this pathogen, suggesting that the viral inclusion model could apply more broadly across related viral families. That possibility alone makes this line of investigation one of the most consequential in current virology research.
The Path Forward in Influenza Research
Research into the influenza A virus has long focused on surface proteins as vaccine and drug targets. This new understanding of genome assembly at the subcellular level represents a meaningful shift in perspective. If the viral inclusion compartments can be disrupted or the phase separation process inhibited, it may be possible to prevent new strains from forming altogether, rather than simply treating infection after it occurs.
FOMAT conducts clinical research across multiple therapeutic areas, including infectious disease. To learn more about active studies, visit FOMAT’s patient studies page.
For the full source of this research, see R&D Magazine.